febrero 01, 2019

Cosentyx is a human interleukin-17A antagonist

According to pooled data from four Phase 3 estudios, el tratamiento con Sechukinumb (Cosentyx; Novartis) was associated with improvement in mobility, self-care, and usual activities (e.g., work, estudio, housework, family or leisure activities) when compared with placebo in patients with moderate-to-severe plaque psoriasis.

En el borrado, ACCESORIO, CARACTERÍSTICA, y ensayos coyuntura, los pacientes con psoriasis que reportaron problemas en estas medidas de calidad de vida (a través del cuestionario EQ-5D-3L) fueron aleatorizados para recibir 300 mg o placebo secukinumab y se evaluaron en las semanas 4, 8, y 12. Results showed that at week 4, the percentage of patients reporting no problems in mobility (60.7%), self-care (71.4%), or change in usual activities (63.8%) was higher in the secukinumab group than in the placebo arm (38.5%, 40.9%, y 31.1%, respectivamente); similar trends were observed at week 8 y 12.

“Moderate-to-severe plaque psoriasis can impact every aspect of a person’s life,” stated Steven R. Feldman, Maryland, Doctor en Filosofía, Wake Forest School of Medicine. “These findings suggest that helping patients feel better through improved quality of life and ability to function should be a goal as important as skin clearance in psoriasis management.”

Cosentyx, a human interleukin-17A antagonist, is FDA-approved for the treatment of: moderate to severe plaque psoriasis in adult patients who are candidates for systemic therapy or phototherapy; adults with active psoriatic arthritis; and adults with active ankylosing spondylitis.

siga @DermAdvisor

Para más información visite Novartis.com.